In psychiatric disorders (excluding schizophrenia), clinical studies reported improvements in mood regulation, anxiety reduction, and cognitive performance, possibly mediated by modulation of the gut-brain axis and reduction of systemic inflammation (Hong et al., 2022
Epub 2020 Nov 16
doi:10.2165/00003088-199324050-00007 222
During the first week of treatment , the recommended starting dose of semaglutide GLP-1 is typically 0.25 mg once a week
Published research on these studies documented outcomes from approximately 900 adult participants, predominantly individuals classified as clinically obese, though one trial included healthy non-obese volunteers
Anderberg RH, Richard JE, Hansson C, et al